Aglaia, a venture capital firm based in Bilthoven, the Netherlands, launched a €65m fund.
Aglaia Oncology Fund II, which is backed by high-net-worth families, institutional investors, including the European Investment Fund (EIF), will invest in ten to fifteen biotechnology startups which are in the process of developing innovative technologies aimed at preventing and curing cancer.
Led by Partner Mark Krul, the firm currently has three funds under management focused exclusively on oncology.
FinSMEs
18/09/2014